4D Medical (ASX:4DX) share price rises on maiden half-year results

The 4DMedical (ASX:4DX) share price is trading higher today after the company announced its half-yearly results. We take a closer look.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

4DMedical Ltd (ASX: 4DX) shares are on the rise today after the company released its half-year results for the period ending 31 December 2020 (1H21). At the time of writing, the 4DMedical share price is trading 2.06% higher at $1.735. At one point during intraday trading, 4DMedical shares rallied by as much as 7% before retreating to their current levels.

Let's take a look at how the medical imaging company has been performing.

What's driving the 4DMedical share price higher?

The 4DMedical share price is trending higher today after the company posted its first-ever 1H report since listing late last year.

In today's release, the company outlined its progress since its successful initial public offering (IPO) that raised $55.79 million. During the period, 4DMedical received Australian TGA approval for its lung imaging software-as-a-service (SaaS) platform. This is a critical milestone for the company to be able to generate meaningful revenue moving forward and was achieved six months ahead of schedule.

In other news boosting the 4DMedical share price, the company also announced it has secured its first United States research program to advance its lung imaging technology in collaboration with the University of Miami.

Regarding the company's financials, 4D Medical ended the half-year period with $43.04 million cash at bank. The company's revenue from ordinary activities during the half-year was derived from maintenance services relating to its scanners.

This revenue declined 86% from the prior corresponding period (pcp), which included $1.10 million in sales of preclinical hardware. Other income increased 29% to $1.08 million, comprised of tax incentives, grant income, and JobKeeper subsidies.

The company's net loss for the period rose strongly to $13.14 million, up 145% compared to a loss of $5.37 million in the pcp. 4DMedical stated that "the operating result was consistent with management's plans."

Management comments

4D Medical founder and CEO Andreas Fouras addressed the results saying:

The first half of FY21 was an extremely busy period for 4DMedical in which we achieved some major operational milestones, such as the company listing on the Australian Securities Exchange (ASX), as well as making significant progress towards commercialisation in both the U.S. and Australia. I am extremely proud of our team's achievements, particularly whilst faced with COVID-19 which continues to create a level of uncertainty and reduced decision-making capacity, particularly in the U.S.

It has not been a good start to the year for the 4DMedical share price. Year to date, the company's share have fallen by nearly 29%, faring far worse than the All Ordinaries Index (ASX: XAO), which has delivered a 2.3% gain so far this year.

Based on the current 4DMedical share price, the company commands a market capitalisation of around $300 million.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Broker gives its verdict on BHP shares

Let's see what Bell Potter is saying about the Big Australian.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Woman holding gold bar and cheering.
Gold

Why Macquarie expects this surging ASX 200 gold stock could leap another 40%

Macquarie forecasts another year of strong outperformance from this fast-rising ASX 200 gold miner.

Read more »

A young woman looks at here phone as she strides out in an airport dragging her wheelie bag behind her and smiling widely.
Broker Notes

Macquarie tips 15% upside for this ASX 200 industrials stock

Is this transportation business preparing for take-off?

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »